Clinical Trial Update: BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update of BI 860585 as a single agent and in combination with exemestane or paclitaxel in advanced/metastatic solid tumors; results posted with co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• BI 860585 (BI 860585)
• Exemestane (Exemestane)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-01-04